Table 1 characteristics and adverse reactions of participants
EC | TST | P | |
|---|---|---|---|
number | 7351 (50.4%) | 7228 (49.6%) | |
male | 49.1% (3606/7351) | 47.4% (3423/7228) | 0.04 |
age | 18.1 ± 0.8 | 18.1 ± 0.7 | 0.77 |
BMI | 20.9 ± 3.1 | 20.9 ± 3.2 | 0.99 |
total ADR | 1565 (21.3%) | 2499 (34.6%) | 0.000 |
bleeding | 414 (5.63%) | 467 (6.46%) | 0.036 |
dermatodyschroia | 314 (4.27%) | 440 (6.09%) | 0.000 |
induration | 287 (3.90%) | 933 (12.91%) | 0.000 |
swelling | 183 (2.49%) | 258 (3.57%) | 0.000 |
pain | 117(1.59%) | 115(1.59%) | 0.998 |
pruritus | 109 (1.48%) | 112 (1.55%) | 0.742 |
erythema | 48(0.65%) | 76(1.05%) | 0.009 |
blistering | 30 (0.41%) | 27 (0.37%) | 0.738 |
fatigue | 18 (0.24%) | 12 (0.17%) | 0.294 |
headache | 10 (0.14%) | 12 (0.17%) | 0.641 |
rash | 9 (0.12%) | 14 (0.19%) | 0.278 |
nausea | 6 (0.08%) | 11 (0.15%) | 0.212 |
dyspnea | 6 (0.08%) | 5 (0.07%) | 0.784 |
vomiting | 5 (0.07%) | 5 (0.07%) | 1.000* |
body ache | 4 (0.05%) | 3 (0.04%) | 1.000 # |
palpitation | 3 (0.04%) | 5 (0.07%) | 0.504 # |
ulceration | 2 (0.03%) | 4 (0.06%) | 0.449 # |